Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone

Diabetes, Obesity and Metabolism

Volumn 11, Issue 11, 2009, Pages 1009-1016

  Chapell, R ^a   Gould, A L ^a   Alexander, C M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bayesian; Heterogeneity; Meta regression; Network meta analysis; Pioglitazone; Random effects model; Rosiglitazone; Sitagliptin

Indexed keywords

HEMOGLOBIN A1C; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN;

ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; HUMAN; META ANALYSIS; SYSTEMATIC REVIEW;

BAYES THEOREM; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRIAZOLES;

EID: 70350140201     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01084.x     Document Type: Article

References (45)

1. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care 2008, 31:1473-1478. A1c-Derived Average Glucose Study Group
2. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. JAMA 2007, 298:194-206.
3. VanDeKoppel S, Choe HM, Sweet BV. Managed care perspective on three new agents for type 2 diabetes. J Manag Care Pharm 2008, 14:363-380.
4. Treating Type 2 Diabetes: the oral diabetes drugs. 2007, Consumers Union, Consumer Reports Best Buy Drugs,, July 2007
5. Sitagliptin (Januvia) for Type 2 diabetes. Med Lett 2007, 49:1-3. Anonymous
6. Nathan DM. Finding new treatments for diabetes-How many, how fast... how good?. N Engl J Med 2007, 356:437-439.
7. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008, 10:959-969.
8. Derosa G, Cicero AFG, Gaddi A. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled parallel-group trial. Clin Ther 2004, 26:744-754.
9. Derosa G, Cicero AFG, Gaddi A. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombrotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005, 69:5-13.
10. Goldberg RB, Kendal DM, Deeg MA. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547-1554.
11. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002, 25:708-711.
12. Cooper H, Hedges LV. The Handbook of Research Synthesis. 1994, eds., New York, Russell Sage Foundation
13. Cook DJ, Mulron CD, Haynes RB. Systematic reviews: synthesis of the best evidence for clinical decisions. Ann Intern Med 1997, 126:376-380.
14. Kahn KS, ter Riet G, Glanville J, Sowden AJ, Kleijnen J. Undertaking Systematic Reviews of research on effectiveness. 2001, CRD Report Number 4, 2nd edn. NHS Centre for Reviews and Dissemination, University of York,
15. Song F, Altman DG, Glenny A-M, Deeks JJ. Validity of indirect comparison for estimating the efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 2003, 326:1-5.
16. Song F, Glenny AM, Altman DG. Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials 2000, 21:488-497.
17. Bloomgarden ZT, Holmboe ES, Dodis R, Inzucchi SE, Viscoli CM. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy. Diabetes Care 2006, 29:2137-2139.
18. Phatak HM, Yin DD. Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA1c: a meta-analysis of published randomized clinical trials. Curr Med Res Opin 2006, 22:2267-2278.
19. Lunn DJ, Homas A, Best N, Spiegelhalter D. WinBUGS- A Bayesian modeling framework: concepts, structure and extensibility. Stat Comput 2000, 10:325-337.
20. Smith TC, Spiegelhalter D, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 1995, 14:2685-2699.
21. Krenz AJ, Bailey CJ. Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs 2005, 65:385-411.
22. Herman GA, Bergman A, Stevens C. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:4612-4619.
23. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001, 86:280-288.
24. Bolen S, Wilson L, Vassy J. Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults with Type 2 Diabetes, Comparative Effectiveness Review No. 8. 2007, (Prepared by Johns Hopkins Evidence-based Practice Center under Contract No. 290-02-0018)., Rockville, Agency for Healthcare Research and Quality
25. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979-1987.
26. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9:733-745.
27. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006, 28:1556-1568.
28. Herz M, Johns D, Reviriego J. A randomized, double-blind, placebo-controlled clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naïve patients with type 2 diabetes mellitus. Clin Ther 2003, 25:1074-1095.
29. Aronoff S, Mathisen A, Rosenblatt S, Schneider RL, Braithwaite S, Egan JW. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 2000, 23:1605-1611.
30. Hung YJ, Pei D, Kuo SW. Pioglitazone monotherapy improves daily plasma glucose and insulin concentrations in type 2 diabetic subjects: a double-blind, placebo-controlled trial. J Med Sci 2006, 26:19-24.
31. Negro R, Dazzi D, Hassan H, Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol 2004, 29:11-17.
32. Scherbaum WA, Goke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: A double-blind, placebo-controlled study. Horm Metab Res 2002, 34:589-595.
33. Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 2006, 29:1039-1045.
34. Wallace TM, Levy JC, Mathews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004, 21:568-576.
35. Hallsten K, Virtanen KA, Lonnqvist F. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Diabet Med 2004, 21:1280-1287.
36. Lautamaki R, Juhani Airksinen KE, Seppanen M. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease. Diabetes 2005, 54:2787-2794.
37. Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract 2005, 70:20-25.
38. Wolffenbuttel BHR, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000, 17:40-47.
39. Zhu XX, Pan CY, Li GW. Addition of rosiglitazone to existing sulfonylurea treatment in Chinese patients with type 2 diabetes and exposure to Hepatitis B or C. Diabetes Technol Ther 2003, 5:33-42.
40. Aschner P, Mickel C, Kipnes MS, Williams-Herman DE, Lunceford JK, Sanchez M. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637.
41. Charbonnel B, Wo M, Karasik A, Meininger G, Ma JL. Efficacy and safety of dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2538-2643.
42. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP. Once-daily sitagliptin, a dipeptidyl oxpeptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007, 23:1329-1339.
43. Nonaka K, Kakikawa T, Sato A. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008, 79:291-298.
44. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes. Diabetologia 2006, 49:2564-2571.
45. Scott R, Herman G, Zhao P, Chen X, Wu M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007, 61:171-180.